1652 / 1708
Table 1.
Patient Characteristics, Medical Variables, and Assessment Details
Characteristic
Total
(N 113)
Standard-
Dose CSR
PF Boost
(n 51)
Standard-Dose
CSR TB
Boost (n 9)
Reduced-
Dose CSR
PF Boost
(n 28)
Reduced-Dose
CSR TB
Boost (n 23)
P
No.
% No.
% No.
% No.
% No.
%
CSR
111 98.2
Chemotherapy†
102 90.3 41 80.4 9
100.0 27 96.4 23
100.0
.017
Protocol
A
3
2
1
B
21
20
1
C
24
4
20
D
17
14
1
2
E
30
1
8
21
F
2
2
G
4
1
2
H
1
Deceased
22 19.5 12 23.5 3
33.3
6 21.4 1
4.3
.17
Gross total resection‡
83 73.5 30 58.8 7
77.8 24 85.7 20
87.0
.12
Clinical risk (average risk)
67 59.3 17 33.3 4
44.4 23 82.1 22
95.7
.001
Hydrocephalus
Presence at diagnosis
90 79.6 39 76.5 5
55.6 25 89.3 19
82.6
.16
Requiring CSF diversion
54 47.8 18 35.0 5
55.6 14 50.0 15
65.2
.10
Third ventriculostomy
6
5.3
2
3.9 0
0.0
1
3.6 3
13.0
.32
EVD only
18 15.9
2
3.9 3
33.3
5 17.9 8
34.8
.004
VPS
30 26.5 14 27.5 2
22.2
8 28.6 4
14.4
.78
1 revision
17 15.0
9 17.6 2
22.2
3 10.7 3
13.0
.79
Mutism§
25 22.1
7 13.7 2
22.2
9 32.1 6
26.1
.26
Motor deficits
18 15.9
8 15.7 2
22.2
3 10.7 5
21.7
.71
Cranial nerve deficits¶
2
1.8
2
3.9 0
0.0
0
0.0 0
0.0
.49
Meningitis
9
8.0
5
9.8 1
11.1
2
7.1 0
0.0
.47
Male sex
79 69.9 39 76.5 8
88.9 19 67.9 11
47.8
.049
Age at diagnosis, years
.29
Mean
7.51
7.89
8.44
6.54
7.48
SD
3.37
3.69
3.69
3.32
3.47
Range
1.09-14.95
1.92-14.54
3.53-14.48
1.69-13.64
1.09-14.95
Time from diagnosis to first assessment, years#
.13
Mean
1.21
1.61
0.82
0.93
0.77
SD
1.68
2.16
0.93
1.14
0.95
Range
0.05-8.73
0.05-8.73
0.08-2.48
0.10-5.33
0.05-4.11
Time from diagnosis to last assessment, years
.001
Mean
6.06
7.28
3.2
6.8
3.26
SD
3.42
3.49
1.17
3.42
1.51
Range
1.47-14.16
1.63-14.16
2.05-5.17
2.25-12.39
1.47-5.63
No. of assessments
.34
Average
3
3
2
3
2
Range
1-7
1-7
1-6
1-7
1-6
Patients seen for a single assessment
32 28.3 17 33.3 4
44.4
3 10.7 8
34.8
.60
NOTE. Test versions used to assess intellectual functioning included: Wechsler Intelligence Scale for Children (eds 3 and 4), Wechsler Preschool and Primary Scale
of Intelligence (revised and ed 2), Wechsler Abbreviated Scale of Intelligence, and Wechsler Adult Intelligence Scale (eds 3 and 4).
Abbreviations: CSF, cerebrospinal fluid; CSR, craniospinal irradiation; EVD, external ventricular drain; PF, posterior fossa; SD, standard deviation; TB, tumor bed;
VPS, ventriculoperitoneal shunt.
P
values reflect
2
analyses conducted between four radiation treatment groups.
†Chemotherapy protocols and associated agents are as follows: A, Baby POG (cyclophosphamide, vincristine, cisplatin, and etoposide); B, ICE (ifosfamide,
carboplatin, and toposide); C, CCG 9961 (vincristine, lomustine/cyclophosphamide, and cisplatin); D, POG 9631 (etoposide, cisplatin, cyclophosphamide, and
vincristine); E, SJMB 03 (vincristine, cisplatin, and cyclophosphamide); F, ACNS 0331 (vincristine, cisplatin, lomustine, and cyclophosphamide); G, 99703 (cisplatin,
vincristine, cyclophosphamide, and etoposide); and H, MOPP (mechloroethamine, vincristine, procarbazine, and prednisone). Patients who did not receive
chemotherapy were treated before 1999.
‡Data unavailable for one patient.
§Patients classified as having mutism if they had diminished speech output, linguistic difficulties, or dysarthria after surgery.
Patients classified as having motor deficits if they had ataxia, dysmetria, or hemiparesis on neurologic examination.
¶Patients classified as having cranial nerve deficits if they had any cranial nerve palsy on neurologic examination (eg, seventh nerve palsy as diagnosed by
facial weakness).
#Seventy-six patients assessed within 12 months from diagnosis.
Moxon-Emre et al
1762
© 2014 by American Society of Clinical Oncology
J
OURNAL OF
C
LINICAL
O
NCOLOGY
2015 from 139.18.235.208
Information downloaded from
jco.ascopubs.organd provided by at UNIVERSITAETSKLINIKUM LEIPZIG on February 17,
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.